Table of contents


On 22 October 2007, orphan designation (EU/3/07/492) was granted by the European Commission to the Weinberg Group LLC, United Kingdom, for iodine (131I) chlorotoxin for the treatment of glioma.

The sponsorship was transferred to The Weinberg Group Limited, United Kingdom, in March 2009, to Biological Consulting Europe Ltd, United Kingdom, in December 2010 and subsequently to Eisai Europe Limited, in June 2011.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2018 on request of the Sponsor.

Key facts

Active substance
Iodine (131I) chlorotoxin
Disease / condition
Treatment of glioma
Date of first decision
EU designation number

Sponsor's contact details

Eisai Europe Limited
European Knowledge Centre
Mosquito Way
Herts AL10 9SN
United Kingdom
Telephone: +44 (0) 845 676 5089
Telefax: +44 (0) 845 676 1504

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating